Latest R-Tech Ueno Ltd. Stories
TOKYO, Jan. 24, 2011 /PRNewswire/ -- R-Tech Ueno, Ltd.
TOKYO, Aug. 16 /PRNewswire/ -- R-Tech Ueno, Ltd., together with Sucampo Pharmaceuticals, Inc. ("Sucampo") and Sucampo AG ("SAG"), has requested arbitration against Takeda Pharmaceutical Co. Ltd. ("Takeda").
TOKYO, July 15 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 15 the completion of the Phase II clinical study on the ophthalmic solution UF-021 (product name Ocuseva (TM)) under development as a therapeutic drug for retinitis pigmentosa (Note 1).
TOKYO, June 10 /PRNewswire/ -- Sucampo Pharmaceuticals, Inc.
TOKYO, May 6 /PRNewswire/ -- The Sanda factory of R-Tech Ueno, Ltd. has received notice from the U.S. Food and Drug Administration (FDA) that its facility has been classified as acceptable for the production of pharmaceuticals by meeting compliance with U.S. cGMP regulations (see the note below).
TOKYO, Oct. 6 /PRNewswire/ -- R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness) (Note 1).
TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd.
TOKYO, July 21 /PRNewswire/ -- R-Tech Ueno, Ltd.
- A handkerchief.
- In general, any miraculous portrait of Christ.